PANKU-Lung03: what clinicians are saying
izalontamab brengitecan (BL-B01D1) in recurrent small cell lung cancer · NCT06500026 ↗ · Phase 3 · Sichuan Baili Pharmaceutical Co., Ltd.
A medical oncologist sees earlier iza-bren responses as suggesting benefit in PANKU-Lung03, but remains concerned about treatment-related deaths despite no observed ILD. Another medical oncologist emphasizes that hematologic toxicity was generally managed with supportive care. Direct trial commentary is limited: these safety assessments concern earlier iza-bren evidence, and the sources reviewed for this edition do not establish an advantage over topotecan.
Created with AI · how we check it
- edition 1
- commentary checked Nov 19, 2026
- 34 verified statements
This edition $750, with MCP access for your AI agent. Get this report
5 findings, and what sits behind each
01. Iza-bren: why a clinician sees phase Ib response as a signal for phase III efficacy
2 of the report's 4 cited clinicians · 9 statements from 2 speakers in 4 sources · 7 passages
Limitations recorded: 3.
Draws on: The comparison, Population and setting, Primary endpoint: Overall survival (OS), Secondary endpoints, Safety and tolerability.
02. HER3 versus EGFR: what speakers say
2 of the report's 4 cited clinicians · 10 statements from 2 speakers in 4 sources · 6 passages
Limitations recorded: 3.
Beyond the trial population
03. Phase Ib iza-bren: where clinicians split on the safety assessment
2 of the report's 4 cited clinicians · 7 statements from 2 speakers in 4 sources · 7 passages
Limitations recorded: 2.
04. Phase I iza-bren: clinicians highlight ORR, but one flags fatal TRAEs
3 of the report's 4 cited clinicians · 12 statements from 3 speakers in 5 sources · 9 passages
Limitations recorded: 3.
05. Other phase III ADC trials: why a clinician expects Topotecan to give way
1 of the report's 4 cited clinicians · 1 statement from 1 speaker in 1 source · 1 passage
Limitations recorded: 1.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 5
2 of the report's 4 cited clinicians
Iza-bren: why a clinician sees phase Ib response as a signal for phase III efficacy
9 statements from 2 speakers in 4 sources
1 of the 2 named speakers in this finding holds this view, a confirmed clinician
- 9
- statements
- 7
- passages
- 4
- sources
- 2
- speakers
What the statements areViews 3Questions and uncertainty 1Clinical experience 0Comparisons 2Restated results and context 3Statement-to-passage links (a passage can back several statements)Supporting a statement 9Giving context 0Recorded with the findingLimitations: 3
3 posts and articles · 1 publication
Draws on: The comparison, Population and setting, Primary endpoint: Overall survival (OS), Secondary endpoints, Safety and tolerability.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
3 of the 5 findings and 14 of the 34 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (9)
ADC, antibody–drug conjugate; EGFR, epidermal growth factor receptor; HCP, healthcare professional; ILD, interstitial lung disease; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; ORR, objective response rate; OS, overall survival; SCLC, small cell lung cancer.
The full PANKU-Lung03 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians need PANKU-Lung03 to show about objective response, overall survival and fatal treatment-related toxicity before using izalontamab brengitecan rather than topotecan for recurrent SCLC after first-line platinum-based chemotherapy plus anti-PD-(L)1 therapy?
From finding F3 (9 statements from 2 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 13commentary sources screened
- 6sources cited by verified statements
- 4named in screened sources
- 4speakers cited in the report
- 4cited speakers with a verified identity
4 cited clinicians, speakers with a confirmed clinical role, of them 4 physicians. By role and specialty:
- 4 physician, Medical oncology
Also in the sources: 1 organizational or shared account, not counted as people.
- 34verified statements, each linked to its source
- 12of them from speakers with a confirmed clinical role
- 5findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 34 | Paid |
| Who said each statement: the cited speakers | 4 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 4 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 10 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
9 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Overall survival (OS) | 6 | 4 |
| Secondary endpoints | 6 | 4 |
| Population and setting | 7 | 4 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 3 | 2 |
| Safety and tolerability | 3 | 3 |
| Design and conductno commentary found | 0 | 0 |
| Dual-target rationale and exploratory receptor biomarkers | 3 | 3 |
| Platinum sensitivity and prior irinotecan | 1 | 1 |
| Phase III expectations drawn from earlier evidence | 4 | 3 |
| Broader ADC expectations for topotecan's role | 1 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
34 verified statements from 6 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Posts · 17 statements · 50% | ||||
| X threads | 17 | 5 | 13 | |
| Primary sources · 17 statements · 50%cited for context, not screened | ||||
| Publications | 17 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 7 / quarter
- Screened window
- May 24, 2025 → Oct 24, 2026
- Cited window
- May 30, 2025 → Sep 13, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy
- Registry
- NCT06500026
- Study IDs
- BL-B01D1-304
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Collaborators
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 722 actual
- Registered
- 2024-07-15
- Start
- 2024-08-07 actual
- Primary completion
- 2026-12 estimated
- Primary endpoint
- Overall survival (OS)
- Interventions
- 2 registered
More on: Small cell lung cancer
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 50 sources about other trials or topics are not included.
- Discussion was identified mainly through the trial identifier and known drug names. Unnamed references, spelling variants and clinical-decision discussions about relapsed SCLC may therefore be missing.
- The detailed efficacy and safety material concerns the supporting NCT05194982 phase Ib study. It must not be read as NCT06500026 results or as a head-to-head comparison with topotecan.
Show all 8 known gaps +Fewer −
- The reviewed accounts report different response estimates in 2025 and 2026 without explaining the differences. They do not establish why estimates differ or that any author changed their view.
- No protocol text or exact regulatory label for BL-B01D1 was available in the sources reviewed. Detailed operational requirements and licensed-use implications cannot be established here.
- Small subgroup analyses and exploratory biomarkers limit conclusions about treatment-history effects, receptor-based selection and mechanism.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 19, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. PANKU-Lung03 (NCT06500026): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/panku-lung03-nct06500026
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "PANKU-Lung03" (NCT06500026), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "panku-lung03-nct06500026". If you cannot make requests, read https://www.erudio.com/reports/panku-lung03-nct06500026.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06500026", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06500026 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/panku-lung03-nct06500026.json
curl https://www.erudio.com/reports/panku-lung03-nct06500026.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "panku-lung03-nct06500026" })release be14be9482f2b50bff0a9c5ac413ae081cc74f9ce5335e143b94ddbc5a271418
Questions
How much does the PANKU-Lung03 report cost?
One edition costs $750 (Focused · 34 verified statements · 12 from 4 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the PANKU-Lung03 report cover?
34 statements from 6 sources (5 posts, 1 paper), 12 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the PANKU-Lung03 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "panku-lung03-nct06500026" }) previews it and create_order({ "report": "panku-lung03-nct06500026", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the PANKU-Lung03 report?
Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.